Navigation Links
Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
Date:6/12/2008

tained clinical effect in belimumab-treated patients from Week 52 to Week 160 includes:

-- An increase from 46% to 52% among serologically active patients based

on the combined response rate selected as the primary efficacy endpoint

of the Phase 3 trials (intention-to-treat analysis).

-- A decrease over time in the overall frequency of SLE disease flares,

and in the frequency of severe disease flares, in patients who remained

on belimumab through three years, as measured by the SELENA SLEDAI

flare index.

-- A greater proportion of patients in the belimumab group reduced their

prednisone dose from baseline compared with the placebo group in the

double-blind phase of the study, and this number continued to increase

through three years.

-- Reversion of autoantibody levels from positive to negative

(anti-dsDNA, anti-RNP, anti-Smith).

-- Stable reductions in immunoglobulins, with no increase in infections or

infectious events over time.

-- An increase in C3 and C4 complement among patients with low complement

at baseline.

About the Phase 2 Study of LymphoStat-B in SLE

The primary objectives of the Phase 2 study were to evaluate the efficacy and safety of belimumab (LymphoStat-B) plus standard of care, versus placebo plus standard of care. A total of 449 patients with active SLE were randomized to receive one of three different doses of belimumab or placebo (1, 4 or 10 mg/kg) administered intravenously over a 52-week treatment period, in addition to standard-of-care therapy. At the end of 52 weeks, 345 patients chose to participate in an optional 24-week extension phase of the study, during which all patients received belimumab. At Week 76, 296 patients chose to remain on belimumab treatment in an open-label long-term continuation phase of the Phase 2 trial, in which all patients are receiving 10 mg/kg belimumab. As o
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
3. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
4. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
5. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
6. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. First Human Implant of New Archus Orthopedics Facet Replacement System
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... Mass. , July 10, 2014 Decision ... report awareness of the U.S. Food and Drug Administration,s ... new phosphate binder Velphoro, which was approved by the ... in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... The Medical Oncology Association of Southern California ... an agreement to work together to expand use ... costs of cancer care in Southern California. ... and distribution services to help health care professionals, ...
... The American Society of Bariatric Physicians (ASBP) is sad ... go out to his family, friends and fans.  The recent ... a contributing factor to his death are concerning and bring ... prescribed. While the specific details of Bubba ...
Cached Medicine Technology:Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 2Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 3Physicians Who Treat Obesity Respond to the News of Bubba Smith's Overdose 2
(Date:7/11/2014)... repaired knee Anterior Cruciate Ligament (ACL) happens all too ... the American Orthopaedic Society for Sports Medicine,s (AOSSM) Annual ... risk factors may minimize the chance of a future ... few risk factors such as, age, activity level and ... of re-injury," said lead author, Christopher C. Kaeding, MD ...
(Date:7/11/2014)... July 11, 2014 With the maturity ... requirements on comfort, the installation rate of Chinese car ... the installation rate exceeded 88% and the demand outnumbered ... the next few years, Chinese car electric window regulator ... 2017, the market size is expected to exceed 110 ...
(Date:7/11/2014)... Wild by Nature, a natural and organic supermarket ... opening a fifth store to be located in West Islip, ... the largest selections of wheat and gluten-free products available. With ... stores have become a one-stop shop for anyone who needs ... gluten intolerance, is a spectrum of disorders, including celiac disease, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 B. E. Smith, ... providers, has been retained to lead a national chief ... in Bend, Ore. The top executive search firm ... placed more than 900 healthcare executives into organizations. , ... St. Charles Health System is the largest provider of medical ...
(Date:7/11/2014)... the experienced dressmaker in the world, has become one ... to beach wedding dresses . Recently, the firm ... in its online shop. Included in the new range ... has been considered as one of the best garment ... spokesman, BellasDress provides superb special occasion gowns and great ...
Breaking Medicine News(10 mins):Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 2Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 3Health News:China Car Electric Window Regulator Industry to Grow at CAGR of 10% to 2017 Says a New Research Report at ChinaMarketResearchReports.com 4Health News:Wild by Nature Opens New Location 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 2Health News:St. Charles Health System Retains B. E. Smith to Recruit New CNO 3Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2
... to treat kidney cancer also targets a genetic mutation active ... (AML), the most common and lethal form of adult leukemia, ... Center report in the Jan. 29 edition of the Journal ... clinical trial, the drug sorafenib reduced the median percentage of ...
... Enforce PROTONIX Patent -, MADISON, N.J., Jan. 29 ... Nycomed, today announced the U.S. launch of Wyeth,s,own generic ... of generic pantoprazole tablets in the U.S. by Teva ... version of PROTONIX,will be distributed by Prasco starting today., ...
... Funding for Bioscience Summer Internship Program Over ... ... Foundation today,awarded $6.5 million to the Translational Genomics Research Institute,(TGen) as ... TGen for the next 25 years. The program helps cultivate new,scientific ...
... 29 At an Election Day,candidate forum in Tampa, ... Mitt Romney told a crowd of the,organization,s conservative seniors ... Hillarycare is not the answer., "I am convinced ... issue and,get our citizens insured but do it in ...
... Nektar,Therapeutics, (Nasdaq: NKTR ) President and Chief ... the upcoming Merrill Lynch,Pharmaceutical, Biotechnology & Medical Device Conference ... on Tuesday, February 5, 2008 at 1:00 p.m.,ET., ... a live,audio-only Webcast through a link posted on the ...
... Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ... it will be participating in Merrill Lynch,s 19th ... New York on,February 5, 2008, at 8:00 a.m. ... presentation can be accessed via Zimmer,s,Investor Relations website ...
Cached Medicine News:Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 2Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 3Health News:Wyeth Announces Launch of Own Generic Version of PROTONIX 2Health News:Wyeth Announces Launch of Own Generic Version of PROTONIX 3Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 2Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 3Health News:Helios Education Foundation Invests $6.5 Million in New Partnership with TGen 4
... Operation: , Double Burst : 2 60-ms bursts of ... s (1 pulse/s) , Tetanus: 50 Hz (50 ... Single (4 pulses/2 s) , Output Current: Adjustable from ... pulses (200-us duration) , Indicators: Battery LED (green) indicates ...
... of Operation: , Standby: A standby switch maintains ... , Twitch: 1 s (1 pulse/s) , ... (4 pulses/2 s) , Output Current: Adjustable from ... Monophasic pulses (200-us duration) , Indicators: Battery LED ...
Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...
... the newest peripheral nerve stimulator from B. Braun ... stimulators providing advanced digital technology. , ,Your ... HNS11 allows the localization of practically all mixed ... ,An additional optional component for the HNS11 ...
Medicine Products: